Journal of Comparative Effectiveness Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Access in all areas? a round up of developments in market access and health technology assessment: part 4
J Comp Eff Res. 2024 Apr 22:e240060. doi: 10.57264/cer-2024-0060. Online ahead of print.ABSTRACTIn this latest update, we look at recent developments in market access including the pricing agreement of Libmeldy® by the Beneluxa Initiative, the financial impact of managed entry agreements in Italy and the restructuring of Agenzia Italiana del Farmaco (AIFA). We also highlight the collaboration between FINOSE and the New Expensive Drug (NED) section of the Nordic Pharmaceutical Forum.PMID:38647164 | DOI:10.57264/cer-2024-0060 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 22, 2024 Category: General Medicine Authors: Alice Beattie Catrin Treharne Sreeram V Ramagopalan Source Type: research

Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Conclusion: Disease progression was associated with significant increases in HCRU and costs. Delays in progression were associated with lower cumulative healthcare costs. Earlier use of more clinically effective treatments to delay progression may reduce the economic burden among these patients.PMID:38647165 | DOI:10.57264/cer-2023-0166 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 22, 2024 Category: General Medicine Authors: Clara Lam Brandon Diessner Katherine Andrade Sydnie Stackland Leah Park Sandhya Mehta Feng Lin Winghan Jackie Kwong Source Type: research

Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value
Conclusion: IMPERIAL data suggest initial treatment with Eluvia extends the time patients spend without undergoing reintervention. This extension may be associated with cost savings in relevant time frames.PMID:38606556 | DOI:10.57264/cer-2024-0025 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 12, 2024 Category: General Medicine Authors: William A Gray Yoshimitsu Soga Masahiko Fujihara Osamu Iida Anvar Babaev Daizo Kawasaki Thomas Zeller David O'Connor Michael R Jaff Anna M Chavez Stefan M üller-Hülsbeck Source Type: research

Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema
J Comp Eff Res. 2024 May;13(5):e240041. doi: 10.57264/cer-2024-0041. Epub 2024 Apr 12.NO ABSTRACTPMID:38606574 | DOI:10.57264/cer-2024-0041 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 12, 2024 Category: General Medicine Authors: Maureen Watt Mia Malmenas Katrin Haeussler Source Type: research

Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema
J Comp Eff Res. 2024 Apr 12:e240041. doi: 10.57264/cer-2024-0041. Online ahead of print.NO ABSTRACTPMID:38606574 | DOI:10.57264/cer-2024-0041 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 12, 2024 Category: General Medicine Authors: Maureen Watt Mia Malmenas Katrin Haeussler Source Type: research

Comparing the outcomes and costs of cardiac monitoring with implantable loop recorders and mobile cardiac outpatient telemetry following stroke using real-world evidence
Conclusion: The use of MCOT versus ILR as the primary monitor following IS was associated with significant decreases in readmission, lower costs for the initial IS and total care over the next 18 months, significantly lower mortality for patients with complications and comorbidities at the index stroke, and a trend toward improved survival across all patients.PMID:38602503 | DOI:10.57264/cer-2024-0008 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 11, 2024 Category: General Medicine Authors: Vincent Norlock Reynaldo Vazquez Alexandria Dunn Christian Siegfried Manish Wadhwa Goran Medic Source Type: research